Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 12Gynecologic 3Thoracic 2Genitourinary 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 73Carcinoma, Renal Cell 36Urinary Bladder Neoplasms 25Carcinoma, Transitional Cell 14Neoplasm Metastasis 12Melanoma 12Ovarian Neoplasms 11Lung Neoplasms 11Colorectal Neoplasms 11Clear-cell metastatic renal cell carcinoma 10Carcinoma, Non-Small-Cell Lung 9Breast Neoplasms 9Wilms Tumor 8Ureteral Neoplasms 8Pancreatic Neoplasms 8Carcinoma, Hepatocellular 8Lymphoma, Non-Hodgkin 7Glioma 7Urethral Neoplasms 6Sarcoma 6Neuroblastoma 6Hepatoblastoma 6Uterine Cervical Neoplasms 5Rhabdoid Tumor 5Osteosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Medulloblastoma 5Histiocytosis, Langerhans-Cell 5Ependymoma 5Central Nervous System Neoplasms 5

Interventions

Early Intervention, Educational 5Radiotherapy 4Psychiatric Rehabilitation 4sargramostim 3pembrolizumab 3Trastuzumab 3Methods 3palbociclib 2cediranib 2Standard of Care 2Specimen Handling 2Mental Status and Dementia Tests 2Magnetic Resonance Spectroscopy 2Irinotecan 2Interleukin-12 Subunit p35 2Interferon-alpha 2Fluorouracil 2Fluorodeoxyglucose F18 2Erlotinib Hydrochloride 2Docetaxel 2Counseling 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1sapanisertib 1relatlimab 1pertuzumab 1osimertinib 1orantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rectal Neoplasms × Specimen Handling × Genitourinary × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05722288 2025-08-29

Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers

City of Hope Medical Center

Phase 2 Recruiting
60 enrolled
GastrointestinalGenitourinary

Prostatic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡